aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary SarcoidosisGlobe Newswire•01/09/2026•20:360 ShareWhiz InsightsGenerateNo content available.
